Summary: A single dose of psilocybin, the active compound in psychedelic “magic” mushrooms, produced long-lasting reductions in neuropathic (nerve) pain in mice and markedly improved the effectiveness of the commonly prescribed pain medication gabapentin. The work, led by researchers at the University of Reading and published in Communications Biology, suggests psilocybin reshapes pain-processing networks in the brain, creating a persistent reset that allows existing non-addictive treatments to work better.
The study shows that psilocybin’s benefit is not just a short-lived blocking of pain signals. Instead, a single administration reorganised how the brain handles pain, producing measurable relief within about two hours and maintaining effects for several weeks—well beyond the time the drug itself remained in the animals’ systems. Crucially, when gabapentin was given weeks after the psilocybin dose—at a point when psilocybin’s direct pain relief had faded—it produced substantially stronger and longer-lasting analgesia than it did in animals that had not previously received psilocybin.
Key findings
- Durable network reset: One dose of psilocybin produced sustained anti-nociceptive effects in mice with chronic nerve injury. Relief appeared quickly and lasted for weeks, implying a reconfiguration of pain-processing circuits rather than a temporary blockade of signals.
- Enhanced gabapentin efficacy: Gabapentin, a standard treatment for neuropathic pain, produced a pronounced and extended analgesic response when administered weeks after psilocybin. In contrast, gabapentin’s effect was substantially weaker in animals without prior psilocybin exposure.
- Clinical relevance: An estimated 30–50% of people with neuropathic pain do not achieve adequate relief from gabapentin when used alone. The new preclinical evidence suggests psilocybin could act as a primer that restores or amplifies the therapeutic action of existing, non-addictive drugs.
- Safety and ethics in experiment design: The research adhered to UK Home Office regulations and the 3Rs principles (Replacement, Reduction, Refinement), using a small, well-controlled cohort of animals and minimizing distress while extracting multiple outcome measures from the same subjects.
- Sex-balanced validation: Analgesic effects were observed in both male and female mice, addressing a historic sex bias in pain research and improving the generalisability of the findings.
Study context and implications
Chronic neuropathic pain is difficult to treat and often resistant to commonly prescribed medications. Existing high-tier pain treatments can carry serious side effects or a risk of dependence. The authors propose a novel therapeutic strategy: using a single psilocybin dose to induce long-lasting reorganisation of brain pain networks, thereby enabling standard-of-care drugs like gabapentin to regain or increase their effectiveness without requiring chronic dosing of psychedelic compounds or resorting to addictive analgesics.
How this works — plain language answers
Q: How can one dose of psilocybin relieve nerve pain for weeks?
A: The researchers found that psilocybin does more than temporarily block a pain signal. It appears to remodel how pain-processing networks are wired in the brain, changing the baseline interpretation of pain so that relief persists long after the molecule has been cleared from the body.
Q: Why does gabapentin become more effective after psilocybin?
A: Psilocybin seems to prime the brain’s networks. When gabapentin was given weeks after psilocybin, the drug produced extended pain relief lasting up to four days in the animal model, whereas gabapentin produced much weaker effects without prior psilocybin. In other words, the network reset makes the brain more responsive to established medications.
Q: Would patients need to experience psychedelic effects repeatedly to manage pain?
A: Not according to this preclinical work. The benefit appears to come from a single, isolated dose that induces a lasting change in pain networks. After that reset, routine non-psychedelic medications could maintain symptom control more effectively, potentially avoiding ongoing psychedelic exposure or heavier addictive options.
Editorial notes
- This article was prepared with editorial input from Neuroscience News staff.
- The peer-reviewed journal paper was examined in full and additional context has been provided by staff writers.
About this research
Author: Ollie Sirrell, University of Reading. Source: University of Reading. Contact: Ollie Sirrell – University of Reading. Image credit: Neuroscience News.
Original research: Psilocybin ameliorates neuropathic pain-like behaviour in mice and facilitates gabapentin-mediated analgesia. Authors: Tatum Askey, Daniel Allen-Ross, Daniil Luzyanin, Reena Lasrado, Gary Gilmour, Stephen P. Hunt, Francesco Tamagnini, Maqsood Ahmed, Gary J. Stephens & Maria Maiarú. Published in Communications Biology. DOI: 10.1038/s42003-026-10065-7. (Open access)
Abstract (summary)
The study demonstrates that a single dose of psilocybin produces sustained anti-nociceptive effects in chronic neuropathic pain models in male and female mice, with effects primarily mediated by 5-HT2A receptors. Psilocybin significantly potentiates the analgesic efficacy of gabapentin, providing the first preclinical evidence that a psychedelic compound can prime pain networks to enhance existing treatments. These results offer a potentially new therapeutic strategy for patients who do not respond to standard-of-care monotherapy and highlight the translational potential for improving chronic pain management by enabling longer-lasting changes in pain-processing networks and increasing the utility of established analgesics.